BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 6176669)

  • 1. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
    Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
    J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.
    Fox BA; Rosenberg SA
    Cancer Immunol Immunother; 1989; 29(3):155-66. PubMed ID: 2786456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits.
    Geller RL; Smyth MJ; Strobl SL; Bach FH; Ruscetti FW; Longo DL; Ochoa AC
    J Immunol; 1991 May; 146(10):3280-8. PubMed ID: 1673980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of effector-target conjugates for cloned human natural killer and human lymphokine activated killer cells by flow cytometry.
    Callewaert DM; Radcliff G; Waite R; LeFevre J; Poulik MD
    Cytometry; 1991; 12(7):666-76. PubMed ID: 1782834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.
    Mazumder A; Grimm EA; Rosenberg SA
    Cancer Immunol Immunother; 1983; 15(1):1-10. PubMed ID: 6603260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor.
    Lagoo-Deenadayalan S; Lagoo AS; Hardy KJ; Grimm EA
    Lymphokine Cytokine Res; 1992 Aug; 11(4):207-13. PubMed ID: 1420599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.
    Chong AS; Aleksijevic A; Scuderi P; Hersh EM; Grimes WJ
    Cancer Immunol Immunother; 1989; 29(4):270-8. PubMed ID: 2502310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
    Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
    Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes.
    Shau H; Gray JD; Golub SH
    Cancer Immunol Immunother; 1988; 27(3):255-60. PubMed ID: 2972366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells.
    Sedlmayr P; Rabinowich H; Elder EM; Ernstoff MS; Kirkwood JM; Herberman RB; Whiteside TL
    J Immunother (1991); 1991 Oct; 10(5):336-46. PubMed ID: 1790141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.
    Guillou PJ; Sedman PC; Ramsden CW
    Cancer Immunol Immunother; 1989; 28(1):43-53. PubMed ID: 2462468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of natural killer activity of lymphocytes infiltrating human lung cancers.
    Anderson TM; Ibayashi Y; Holmes EC; Golub SH
    Cancer Immunol Immunother; 1987; 25(1):65-8. PubMed ID: 3109739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The specificity of lymphokine-activated killer (LAK) cells in vitro: fresh normal murine tissues are resistant to LAK-mediated lysis.
    Lefor AT; Rosenberg SA
    J Surg Res; 1991 Jan; 50(1):15-23. PubMed ID: 1987427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
    Anderson PM; Bach FH; Ochoa AC
    Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
    Itoh K; Pellis NR; Balch CM
    Cancer Immunol Immunother; 1989; 29(1):57-62. PubMed ID: 2785000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
    Subauste CS; Dawson L; Remington JS
    J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
    Furbert-Harris PM; Evans CH
    Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.